Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4

分组1 - Plus Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.03, compared to a loss of $0.67 per share a year ago, indicating an earnings surprise of +100.00% [1] - The company posted revenues of $1.37 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.02%, although this represents a decline from year-ago revenues of $1.41 million [2] - Plus shares have declined approximately 39.9% since the beginning of the year, contrasting with the S&P 500's decline of 1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $1.15 million, and for the current fiscal year, it is -$0.16 on revenues of $5.16 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 35% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]